<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01444781</url>
  </required_header>
  <id_info>
    <org_study_id>A3L27</org_study_id>
    <secondary_id>U1111-1112-8473</secondary_id>
    <nct_id>NCT01444781</nct_id>
  </id_info>
  <brief_title>Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants</brief_title>
  <official_title>Evaluation of Antibody Persistence Following a Primary Series at 2, 4, and 6 Months on Trial A3L24 and Booster Effect of the DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ Concomitantly Administered With Prevenar™ at 12 to 24 Months of Age in Healthy Latin American Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a follow-up of the primary series vaccination schedule in Study A3L24 (NCT01177722).
      The objectives are:

        -  To describe the antibody persistence to any antigen contained in the investigational
           DTaP-IPV-Hep B-PRP-T vaccine and Infanrix hexa™ prior to the booster dose

        -  To describe the safety and immunogenicity of the booster dose of either DTaP-IPV-Hep
           B-PRP-T or Infanrix hexa™ vaccine.

        -  To describe the immunogenicity of a booster dose of Prevenar™ given at 12 to 24 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All participants who completed trial A3L24 (NCT01177722) will be recruited to participate in
      this trial. Those who received DTaP-IPV-Hep B-PRP-T combined vaccine will be randomized to
      receive either a booster dose of DTaP-IPV-Hep B-PRP-T or Infanrix hexa™ vaccine.

      Those who received Infanrix hexa™ will receive a booster dose of DTaP-IPV-Hep B-PRP-T
      combined vaccine. All participants will receive a booster dose of Prevenar™ concomitantly.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Summary of Diphtheria and Tetanus Post Primary Series Antibodies, Persistence and Booster Response Following Vaccination With Either DTaP-IPV Hep B-PRP T Vaccine or Infanrix Hexa Vaccine</measure>
    <time_frame>Day 140 (Primary series) and Day 0 (Pre-booster)</time_frame>
    <description>Anti-Diphtheria (D) antibodies were measured by a toxin neutralization test. Anti-Tetanus (T) antibodies were measured by enzyme-linked immunosorbent assay (ELISA). Antibody persistence for anti-Diphtheria and anti-Tetanus antibodies was defined as titers ≥0.01 IU/mL and ≥0.1 IU/mL before the booster dose at Day 0. Booster response to Diphtheria and Tetanus was defined as antibody titers ≥0.01 IU/mL and ≥0.1 IU/mL at Day 30 post-booster vaccination.
Day 140 = Primary series; Day 0 = Pre-booster; and Day 30 = Post-booster titers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Summary of Pertussis and Filamentous Haemagglutinin Post Primary Series Antibodies, Persistence and Booster Response Following Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine or Infanrix Hexa Vaccine</measure>
    <time_frame>Day 140 after primary vaccination, Day 0 (pre-vaccination), and Day 30 after final booster vaccination</time_frame>
    <description>Anti-Pertussis toxin (PT) and anti-Filamentous haemagglutinin (FHA) antibodies were measured by ELISA. Antibody persistence for anti-PT and anti-FHA was defined as titers ≥ lower limit of quantitation (LLOQ) before the booster dose at Day 0. Booster responses for PT and FHA at Day 30 were defined as: pre-vaccination antibody concentrations &lt; LLOQ and post-vaccination levels ≥ 4 x LLOQ, pre-vaccination antibody concentrations ≥ LLOQ but &lt; 4 x LLOQ and post/pre vaccination ≥ 4, and pre-vaccination antibody concentrations ≥ 4 x LLOQ and post/pre-vaccination ≥ 2.
Day 140 = Primary series; Day 0 = Pre-booster; and Day 30 = Post-booster titers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Summary of Polio Antibodies Post Primary Series, Persistence and Booster Response Following Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine or Infanrix Hexa Vaccine</measure>
    <time_frame>Day 140 after primary vaccination, Day 0 (pre-vaccination), and Day 30 after final booster vaccination</time_frame>
    <description>Anti-Poliovirus types 1, 2, and 3 antibodies were measured by neutralization assay. Antibody persistence for anti-Poliovirus 1, 2, and 3 was defined as antibody titers ≥8 (1/dil) before the booster dose at Day 0. Booster response to Poliovirus 1, 2, and 3 was defined as antibody titers ≥8 (1/dil) at Day 30.
Day 140 = Primary series; Day 0 = Pre-booster; and Day 30 = Post-booster titers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Summary of Hepatitis B and Haemophilus Influenzae Type B Post Primary Series Antibodies; Antibody Persistence, and Booster Response Following Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine or Infanrix Hexa Vaccine</measure>
    <time_frame>Day 140 after primary vaccination, Day 0 (pre-vaccination), and Day 30 after final booster vaccination</time_frame>
    <description>Anti-Hepatitis B antibodies were measured by the commercially available VITROS ECi/ECiQ Immunodiagnostic System. Anti-Haemophilus influenza type b capsular polyribosyl ribitol phosphate (PRP) antibodies were measured using a Farr type radioimmunoassay that used radiolabeled PRP (3H PRP) in the presence of 36Cl (volume marker). Anti-Hepatitis antibody titers ≥ 10 mIU/mL and ≥ 100 mIU/mL at Day 0 confirmed antibody persistence and booster response at Day 30. Anti-PRP antibody titers ≥ 0.15 µg/ml and ≥ 1.0 µg/ml at Day 0 confirmed antibody persistence and booster response at Day 30.
Day 140 = Primary series; Day 0 = Pre-booster; and Day 30 = Post-booster titers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Summary of Geometric Mean Titers to Vaccine Antibodies Post Primary Vaccination Series; Before and After Booster Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine or Infanrix Hexa Vaccine.</measure>
    <time_frame>Day 140 after primary vaccination, Day 0 (pre-vaccination), and Day 30 after final booster vaccination</time_frame>
    <description>Anti-Diphtheria antibodies were measured by a toxin neutralization test. Anti-Tetanus, anti-PT, and anti-FHA antibodies were measured by ELISA. Anti-Poliovirus types 1, 2, and 3 were measured by neutralization assay. Anti-Hepatitis B antibodies were measured by the commercially available VITROS ECi/ECiQ Immunodiagnostic System. Anti-PRP antibodies were measured using a Farr type radioimmunoassay that used radiolabeled PRP (3H PRP) in the presence of 36Cl (volume marker).
Day 140 = Primary series; Day 0 = Pre-booster; and Day 30 = Post-booster titers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Immune Response Against Serotypes in the Prevenar Vaccine After Booster Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine or Infanrix Hexa Vaccine</measure>
    <time_frame>Day 30 after final booster vaccination</time_frame>
    <description>Anti-Streptococcus pneumococcal type specific antibody (anti-Pn PS) was measured by ELISA. Booster response to pneumococcal serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F was defined as antibody titers ≥0.35 µg/mL at Day 30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Geometric Mean Titers to Prevenar Vaccine Antibodies After Booster Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine or Infanrix Hexa Vaccine</measure>
    <time_frame>Day 30 after final booster vaccination</time_frame>
    <description>Anti-Streptococcus pneumococcal type specific antibody (anti-Pn PS) was measured by ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Booster Response to Vaccine Antigens Before and After Booster Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine or Infanrix Hexa Vaccine By Age Strata</measure>
    <time_frame>Day 0 (pre-vaccination) and Day 30 after final booster vaccination</time_frame>
    <description>Anti-PT and anti-FHA antibodies were measured by ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Geometric Mean Titers to Vaccine Antigens After Booster Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine or Infanrix Hexa Vaccine by Age Strata</measure>
    <time_frame>Day 30 after final booster vaccination</time_frame>
    <description>Anti-Diphtheria antibodies were measured by a toxin neutralization test. Anti-FHA antibodies were measured by ELISA. Anti-Poliovirus types 1, 2, and 3 were measured by neutralization assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting a Solicited Injection Site or Systemic Reactions Following Booster Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine or Infanrix Hexa Vaccine</measure>
    <time_frame>Day 0 up to Day 7 after final booster vaccination</time_frame>
    <description>Solicited injection site: Pain, Erythema, Swelling, and Extensive swelling of vaccinated limb; Solicited systemic reactions: Pyrexia (Temperature), Vomiting, Crying, Somnolence, Anorexia, and Irritability. Grade 3 Injection site: Pain, Cries if limb is moved or reduced movement; Erythema and Swelling, ≥5 cm; Extensive swelling of limb, Severe. Grade 3 Systemic reactions: Pyrexia (Temperature) &gt;39.5˚C; Vomiting, ≥ 6 times per 24 hours or needing parenteral nutrition; Crying, &gt;3 hours; Somnolence, Sleeping often or difficulty waking; Anorexia, refuses ≥3 meals; and Irritability, Inconsolable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting a Solicited Injection Site Following Booster Vaccination With Prevenar Vaccine</measure>
    <time_frame>Day 0 up to Day 7 after final booster vaccination</time_frame>
    <description>Solicited injection site: Pain, Erythema, Swelling, and Extensive swelling of vaccinated limb. Grade 3 Injection site: Pain, cries if limb is moved or reduced movement; Erythema and Swelling, ≥5 cm; and Extensive swelling of limb, Severe.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1106</enrollment>
  <condition>Diphtheria</condition>
  <condition>Tetanus</condition>
  <condition>Whooping Cough</condition>
  <condition>Hepatitis B</condition>
  <condition>Poliomyelitis</condition>
  <arm_group>
    <arm_group_label>Study Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants previously primed with DTaP-IPV-Hep B-PRP~T, will receive one dose of DTaP-IPV-Hep B-PRP~T vaccine + one dose of Prevenar™</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants previously primed with DTaP-IPV-Hep B-PRP~T, will receive one dose of Infanrix hexa™ vaccine + one dose of Prevenar™</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants previously primed with Infanrix hexa™ will receive one dose of DTaP-IPV-Hep B-PRP~T + one dose of Prevenar™.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTaP-IPV-Hep B-PRP~T combined vaccine + Pneumococcal polysaccharide</intervention_name>
    <description>0.5 mL, Intramuscular each into the right and left deltoid muscle</description>
    <arm_group_label>Study Group 1</arm_group_label>
    <other_name>DTaP-IPV-Hep B-PRP~T vaccine</other_name>
    <other_name>Prevenar™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTaP-Hep B-IPV // Hib Vaccine + Pneumococcal polysaccharide</intervention_name>
    <description>0.5 mL, Intramuscular each into the right and left deltoid muscle</description>
    <arm_group_label>Study Group 2</arm_group_label>
    <other_name>Infanrix hexa™</other_name>
    <other_name>Prevenar™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTaP-IPV-Hep B-PRP~T + Pneumococcal polysaccharide vaccine</intervention_name>
    <description>0.5 mL (each), Intramuscular each into the right and left deltoid muscle</description>
    <arm_group_label>Study Group 3</arm_group_label>
    <other_name>DTaP-IPV-Hep B-PRP~T combined vaccine</other_name>
    <other_name>Prevenar™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 12 to 24 months on the day of inclusion.

          -  Informed consent form has been signed and dated by the parent(s) or other legally
             acceptable representative (and by an independent witness(es) if required by local
             regulations).

          -  Subject and parent/guardian are able to attend all scheduled visits and to comply with
             all trial procedures.

          -  Toddlers previously included in Study A3L24 who completed the three-dose primary
             series vaccination of either DTaP-IPV-Hep B-PRP~T or Infanrix hexa™ at 2,4 and 6
             months of age according to protocol (both concomitantly administered with Prevenar™
             and Rotarix™).

        Exclusion Criteria:

          -  Participation in another clinical trial investigating a vaccine, drug, medical device,
             or medical procedure in the 4 weeks preceding the booster vaccinations.

          -  Planned participation in another clinical trial during the present trial period.

          -  Receipt of any vaccine in the 4 weeks preceding the booster vaccinations, except in
             case of pandemic influenza vaccination, which may be received at least two weeks
             before the study vaccines.

          -  Planned receipt of any vaccine in the 4 weeks following the trial vaccinations.

          -  Previous booster vaccination against pertussis, tetanus, diphtheria, poliomyelitis,
             Haemophilus influenzae type b, hepatitis B and pneumococcal infection(s) with either
             the trial vaccine or another vaccine.

          -  Receipt of blood or blood-derived products in the past 3 months, which might interfere
             with assessment of the immune response.

          -  Known or suspected congenital or acquired immunodeficiency; or receipt of
             immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within
             the preceding 3 months; or long-term systemic corticosteroid therapy (prednisone or
             equivalent for more than 2 consecutive weeks within the past 3 months).

          -  Laboratory-confirmed or clinical suspicion of personal or maternal seropositivity for
             Human Immunodeficiency Virus (HIV), hepatitis B, or hepatitis C, as reported by the
             parent/guardian.

          -  History of pertussis, tetanus, diphtheria, poliomyelitis, Haemophilus influenzae type
             b, hepatitis B and pneumococcal infection(s), confirmed either clinically,
             serologically, or microbiologically.

          -  At high risk for opportunistic infection during the trial.

          -  Known systemic hypersensitivity to any of the vaccine components, or history of a
             life-threatening reaction to the vaccine(s) used in the trial or to a vaccine
             containing any of the same substances.

          -  History of contraindication to receipt of pertussis-containing vaccine.

          -  Laboratory-confirmed or clinical suspicion of thrombocytopenia contraindicating
             Intramuscular vaccination.

          -  Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion,
             contraindicating intramuscular vaccination.

          -  History of seizures .

          -  Chronic illness that, in the opinion of the investigator, is at a stage where it might
             interfere with trial conduct or completion.

          -  Receipt of oral or injected antibiotic therapy within 72 hours prior to the first
             blood draw

          -  Febrile illness (temperature ≥ 38.0°C) or moderate or severe acute illness/infection
             (according to investigator judgment) on the day of vaccination.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur SA</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San José de Costa Rica</city>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>Costa Rica</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2011</study_first_submitted>
  <study_first_submitted_qc>September 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2011</study_first_posted>
  <results_first_submitted>June 12, 2014</results_first_submitted>
  <results_first_submitted_qc>July 14, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 16, 2014</results_first_posted>
  <last_update_submitted>July 14, 2014</last_update_submitted>
  <last_update_submitted_qc>July 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diphtheria</keyword>
  <keyword>Tetanus</keyword>
  <keyword>Whooping Cough</keyword>
  <keyword>Hepatitis B</keyword>
  <keyword>Poliomyelitis</keyword>
  <keyword>Pediatric combined vaccine</keyword>
  <keyword>Invasive Hib infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Poliomyelitis</mesh_term>
    <mesh_term>Whooping Cough</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study participants were enrolled from 26 September 2011 through 19 July 2012 at 2 clinic centers in Colombia and Costa Rica.</recruitment_details>
      <pre_assignment_details>A total of 1106 participants who met all of the inclusion and none of the exclusion criteria were randomized and vaccinated in this study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1: DTaP-IPV-Hep B-PRP~T + Prevenar™ Primary and Booster</title>
          <description>Participants who were previously primed with DTaP-IPV-Hep B-PRP~T received one dose of DTaP-IPV-Hep B-PRP~T vaccine and one dose of Prevenar (PCV7)</description>
        </group>
        <group group_id="P2">
          <title>Group2: DTaPIPV-Hep B-PRP~T Primary/Infanrix Hexa+PCV7 Booster</title>
          <description>Participants who were previously primed with DTaP-IPV-Hep B-PRP~T received one dose of Infanrix Hexa vaccine and one dose of PCV7.</description>
        </group>
        <group group_id="P3">
          <title>Group3: Infanrix Hexa Primary/DTaPIPV-Hep B PRP~T+PCV7 Booster</title>
          <description>Participants who were previously primed with Infanrix Hexa vaccine received one dose of DTaP-IPV-Hep B-PRP~T and one dose of PCV7</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="416"/>
                <participants group_id="P2" count="415"/>
                <participants group_id="P3" count="275"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="413"/>
                <participants group_id="P2" count="411"/>
                <participants group_id="P3" count="272"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DTaP IPV Hep B PRP T + Prevenar™ Primary and Booster Group</title>
          <description>Participants who were previously primed with DTaP IPV Hep B PRP T received one dose of DTaP IPV Hep B PRP T vaccine and one dose of Prevenar (PCV7)</description>
        </group>
        <group group_id="B2">
          <title>DTaP IPV Hep B PRP T Primary/Infanrix Hexa+PCV7 Booster Group</title>
          <description>Participants who were previously primed with DTaP IPV Hep B PRP T received one dose of Infanrix Hexa vaccine and one dose of PCV7.</description>
        </group>
        <group group_id="B3">
          <title>Infanrix Hexa Primary/DTaP IPV Hep B PRP T+PCV7 Booster Group.</title>
          <description>Participants who were previously primed with Infanrix Hexa vaccine received one dose of DTaP IPV Hep B PRP T and one dose of PCV7</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="416"/>
            <count group_id="B2" value="415"/>
            <count group_id="B3" value="275"/>
            <count group_id="B4" value="1106"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="416"/>
                    <measurement group_id="B2" value="415"/>
                    <measurement group_id="B3" value="275"/>
                    <measurement group_id="B4" value="1106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.6" spread="3.25"/>
                    <measurement group_id="B2" value="17.6" spread="3.34"/>
                    <measurement group_id="B3" value="17.8" spread="3.26"/>
                    <measurement group_id="B4" value="17.7" spread="3.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="203"/>
                    <measurement group_id="B2" value="186"/>
                    <measurement group_id="B3" value="128"/>
                    <measurement group_id="B4" value="517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="213"/>
                    <measurement group_id="B2" value="229"/>
                    <measurement group_id="B3" value="147"/>
                    <measurement group_id="B4" value="589"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="266"/>
                    <measurement group_id="B2" value="266"/>
                    <measurement group_id="B3" value="172"/>
                    <measurement group_id="B4" value="704"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Costa Rica</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="103"/>
                    <measurement group_id="B4" value="402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Summary of Diphtheria and Tetanus Post Primary Series Antibodies, Persistence and Booster Response Following Vaccination With Either DTaP-IPV Hep B-PRP T Vaccine or Infanrix Hexa Vaccine</title>
        <description>Anti-Diphtheria (D) antibodies were measured by a toxin neutralization test. Anti-Tetanus (T) antibodies were measured by enzyme-linked immunosorbent assay (ELISA). Antibody persistence for anti-Diphtheria and anti-Tetanus antibodies was defined as titers ≥0.01 IU/mL and ≥0.1 IU/mL before the booster dose at Day 0. Booster response to Diphtheria and Tetanus was defined as antibody titers ≥0.01 IU/mL and ≥0.1 IU/mL at Day 30 post-booster vaccination.
Day 140 = Primary series; Day 0 = Pre-booster; and Day 30 = Post-booster titers</description>
        <time_frame>Day 140 (Primary series) and Day 0 (Pre-booster)</time_frame>
        <population>Antibody responses were assessed in the Per Protocol Analysis Set, which includes all persons who did not have any protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: DTaP IPV Hep B PRP T + Prevenar™ Primary and Booster</title>
            <description>Participants who were previously primed with DTaP IPV Hep B PRP T received one dose of DTaP IPV Hep B PRP T vaccine and one dose of Prevenar (PCV7)</description>
          </group>
          <group group_id="O2">
            <title>Group 2DTaP IPV Hep B PRP T Primary/Infanrix Hexa+PCV7 Booster</title>
            <description>Participants who were previously primed with DTaP IPV Hep B PRP T received one dose of Infanrix Hexa vaccine and one dose of PCV7.</description>
          </group>
          <group group_id="O3">
            <title>Group 3Infanrix Hexa Primary/DTaP IPV Hep B PRP T+PCV7 Booster</title>
            <description>Participants who were previously primed with Infanrix Hexa vaccine received one dose of DTaP IPV Hep B PRP T and one dose of PCV7</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Diphtheria and Tetanus Post Primary Series Antibodies, Persistence and Booster Response Following Vaccination With Either DTaP-IPV Hep B-PRP T Vaccine or Infanrix Hexa Vaccine</title>
          <description>Anti-Diphtheria (D) antibodies were measured by a toxin neutralization test. Anti-Tetanus (T) antibodies were measured by enzyme-linked immunosorbent assay (ELISA). Antibody persistence for anti-Diphtheria and anti-Tetanus antibodies was defined as titers ≥0.01 IU/mL and ≥0.1 IU/mL before the booster dose at Day 0. Booster response to Diphtheria and Tetanus was defined as antibody titers ≥0.01 IU/mL and ≥0.1 IU/mL at Day 30 post-booster vaccination.
Day 140 = Primary series; Day 0 = Pre-booster; and Day 30 = Post-booster titers</description>
          <population>Antibody responses were assessed in the Per Protocol Analysis Set, which includes all persons who did not have any protocol deviations.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="396"/>
                <count group_id="O2" value="393"/>
                <count group_id="O3" value="260"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-Diphtheria Day140 ≥0.01 IU/mL (N=392,391,259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="392"/>
                    <measurement group_id="O2" value="391" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="259" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Diphtheria Day 140 ≥0.1 IU/mL (N=392,391,259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="308"/>
                    <measurement group_id="O2" value="290" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="197" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Diphtheria Day 0 ≥0.01 IU/mL (N=390,390,257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="382"/>
                    <measurement group_id="O2" value="378" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="246" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Diphtheria Day 0 ≥0.1 IU/mL (N=390,390,257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156"/>
                    <measurement group_id="O2" value="153" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="70" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Diphtheria Day 30 ≥0.01 IU/mL (N=393,387,254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="393"/>
                    <measurement group_id="O2" value="387" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="254" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Diphtheria Day 30 ≥0.1 IU/mL (N=393,387,254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="393"/>
                    <measurement group_id="O2" value="386" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="254" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Tetanus Day 140 ≥0.01 IU/mL (N=392,391,258)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="392"/>
                    <measurement group_id="O2" value="391" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="258" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Tetanus Day 140 ≥0.1 IU/mL (N=392,391,258)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="392"/>
                    <measurement group_id="O2" value="390" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="258" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Tetanus Day 0 ≥0.01 IU/mL (N=389,387,255)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="389"/>
                    <measurement group_id="O2" value="386" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="255" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Tetanus Day 0 ≥0.1 IU/mL (N=389,387,255)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="289"/>
                    <measurement group_id="O2" value="286" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="196" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Tetanus Day 30 ≥0.01 IU/mL (N=392,385,254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="392"/>
                    <measurement group_id="O2" value="385" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="254" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Tetanus Day 30 ≥0.1 IU/mL (N=392,385,254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="391"/>
                    <measurement group_id="O2" value="385" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="254" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Summary of Pertussis and Filamentous Haemagglutinin Post Primary Series Antibodies, Persistence and Booster Response Following Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine or Infanrix Hexa Vaccine</title>
        <description>Anti-Pertussis toxin (PT) and anti-Filamentous haemagglutinin (FHA) antibodies were measured by ELISA. Antibody persistence for anti-PT and anti-FHA was defined as titers ≥ lower limit of quantitation (LLOQ) before the booster dose at Day 0. Booster responses for PT and FHA at Day 30 were defined as: pre-vaccination antibody concentrations &lt; LLOQ and post-vaccination levels ≥ 4 x LLOQ, pre-vaccination antibody concentrations ≥ LLOQ but &lt; 4 x LLOQ and post/pre vaccination ≥ 4, and pre-vaccination antibody concentrations ≥ 4 x LLOQ and post/pre-vaccination ≥ 2.
Day 140 = Primary series; Day 0 = Pre-booster; and Day 30 = Post-booster titers.</description>
        <time_frame>Day 140 after primary vaccination, Day 0 (pre-vaccination), and Day 30 after final booster vaccination</time_frame>
        <population>Antibody responses were assessed in the Per-protocol Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: DTaP-IPV Hep B-PRP~T + Prevenar™ Primary and Booster</title>
            <description>Participants who were previously primed with DTaP-IPV-Hep B-PRP~T received one dose of DTaP-IPV-Hep B-PRP~T vaccine and one dose of Prevenar (PCV7)</description>
          </group>
          <group group_id="O2">
            <title>Group 2:DTaP-IPV-HepB-PRP~T Primary/Infanrix Hexa+PCV7 Booster</title>
            <description>Participants who were previously primed with DTaP-IPV-Hep B-PRP~T received one dose of Infanrix Hexa vaccine and one dose of PCV7.</description>
          </group>
          <group group_id="O3">
            <title>Group 3:Infanrix Hexa Primary/DTaP-IPV-HepB-PRP~T+PCV7 Booster</title>
            <description>Participants who were previously primed with Infanrix Hexa vaccine received one dose of DTaP-IPV-Hep B-PRP~T and one dose of PCV7</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Pertussis and Filamentous Haemagglutinin Post Primary Series Antibodies, Persistence and Booster Response Following Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine or Infanrix Hexa Vaccine</title>
          <description>Anti-Pertussis toxin (PT) and anti-Filamentous haemagglutinin (FHA) antibodies were measured by ELISA. Antibody persistence for anti-PT and anti-FHA was defined as titers ≥ lower limit of quantitation (LLOQ) before the booster dose at Day 0. Booster responses for PT and FHA at Day 30 were defined as: pre-vaccination antibody concentrations &lt; LLOQ and post-vaccination levels ≥ 4 x LLOQ, pre-vaccination antibody concentrations ≥ LLOQ but &lt; 4 x LLOQ and post/pre vaccination ≥ 4, and pre-vaccination antibody concentrations ≥ 4 x LLOQ and post/pre-vaccination ≥ 2.
Day 140 = Primary series; Day 0 = Pre-booster; and Day 30 = Post-booster titers.</description>
          <population>Antibody responses were assessed in the Per-protocol Analysis Set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="396"/>
                <count group_id="O2" value="393"/>
                <count group_id="O3" value="260"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PT Day 140 ≥2 EU/mL (N=393,391,259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="393"/>
                    <measurement group_id="O2" value="391" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="259" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PT Day 0 ≥2 EU/mL (N=385,382,257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="344"/>
                    <measurement group_id="O2" value="349" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="225" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A-PT Day 30 ≥ 2 EU/mL (N=391,383,254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="391"/>
                    <measurement group_id="O2" value="383" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="254" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PT 4-fold increase (N=380,374,252)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="353"/>
                    <measurement group_id="O2" value="351" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="234" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PT booster response (N=380,374,252)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="375"/>
                    <measurement group_id="O2" value="365" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="245" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA Day 140 ≥2 EU/mL (N=391,390,259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="391"/>
                    <measurement group_id="O2" value="390" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="259" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA Day 0 ≥2 EU/mL (N=389,384,255)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="389"/>
                    <measurement group_id="O2" value="384" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="253" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA Day 30 ≥2 EU/mL (N=390,385,254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="390"/>
                    <measurement group_id="O2" value="385" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="254" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA 4-fold increase (N=384,376,252)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="336"/>
                    <measurement group_id="O2" value="334" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="235" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA booster response (N=384,376,252)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="370"/>
                    <measurement group_id="O2" value="367" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="249" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Summary of Polio Antibodies Post Primary Series, Persistence and Booster Response Following Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine or Infanrix Hexa Vaccine</title>
        <description>Anti-Poliovirus types 1, 2, and 3 antibodies were measured by neutralization assay. Antibody persistence for anti-Poliovirus 1, 2, and 3 was defined as antibody titers ≥8 (1/dil) before the booster dose at Day 0. Booster response to Poliovirus 1, 2, and 3 was defined as antibody titers ≥8 (1/dil) at Day 30.
Day 140 = Primary series; Day 0 = Pre-booster; and Day 30 = Post-booster titers.</description>
        <time_frame>Day 140 after primary vaccination, Day 0 (pre-vaccination), and Day 30 after final booster vaccination</time_frame>
        <population>Antibody responses were assessed in the Per Protocol Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: DTaP IPV Hep B PRP T + Prevenar™ Primary and Booster</title>
            <description>Participants who were previously primed with DTaP IPV Hep B PRP T received one dose of DTaP IPV Hep B PRP T vaccine and one dose of Prevenar (PCV7)</description>
          </group>
          <group group_id="O2">
            <title>Group 2DTaP IPV Hep B PRP T Primary/Infanrix Hexa+PCV7 Booster</title>
            <description>Participants who were previously primed with DTaP IPV Hep B PRP T received one dose of Infanrix Hexa vaccine and one dose of PCV7.</description>
          </group>
          <group group_id="O3">
            <title>Group 3Infanrix Hexa Primary/DTaP IPV Hep B PRP T+PCV7 Booster</title>
            <description>Participants who were previously primed with Infanrix Hexa vaccine received one dose of DTaP IPV Hep B PRP T and one dose of PCV7</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Polio Antibodies Post Primary Series, Persistence and Booster Response Following Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine or Infanrix Hexa Vaccine</title>
          <description>Anti-Poliovirus types 1, 2, and 3 antibodies were measured by neutralization assay. Antibody persistence for anti-Poliovirus 1, 2, and 3 was defined as antibody titers ≥8 (1/dil) before the booster dose at Day 0. Booster response to Poliovirus 1, 2, and 3 was defined as antibody titers ≥8 (1/dil) at Day 30.
Day 140 = Primary series; Day 0 = Pre-booster; and Day 30 = Post-booster titers.</description>
          <population>Antibody responses were assessed in the Per Protocol Analysis Set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="396"/>
                <count group_id="O2" value="393"/>
                <count group_id="O3" value="260"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-Polio 1 Day 140 (N = 338,329,214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="338"/>
                    <measurement group_id="O2" value="329" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="214" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 1 Day 0 (N = 338,326,213)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="334"/>
                    <measurement group_id="O2" value="320" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="210" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 1 Day 30 (N = 339,327,212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="339"/>
                    <measurement group_id="O2" value="327" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="212" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 2 Day 140 (N = 338,327,214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="338"/>
                    <measurement group_id="O2" value="327" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="214" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 2 Day 0(N = 337,328,213)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="335"/>
                    <measurement group_id="O2" value="328" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="213" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 2 Day 30 (N = 340,327,212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="340"/>
                    <measurement group_id="O2" value="327" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="212" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 3 Day 140 (N = 338,328,214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="338"/>
                    <measurement group_id="O2" value="328" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="214" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 3 Day 0 (N = 338,326,213)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="324"/>
                    <measurement group_id="O2" value="309" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="211" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 3 Day 30 (N = 340,326,212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="340"/>
                    <measurement group_id="O2" value="326" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="212" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Summary of Hepatitis B and Haemophilus Influenzae Type B Post Primary Series Antibodies; Antibody Persistence, and Booster Response Following Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine or Infanrix Hexa Vaccine</title>
        <description>Anti-Hepatitis B antibodies were measured by the commercially available VITROS ECi/ECiQ Immunodiagnostic System. Anti-Haemophilus influenza type b capsular polyribosyl ribitol phosphate (PRP) antibodies were measured using a Farr type radioimmunoassay that used radiolabeled PRP (3H PRP) in the presence of 36Cl (volume marker). Anti-Hepatitis antibody titers ≥ 10 mIU/mL and ≥ 100 mIU/mL at Day 0 confirmed antibody persistence and booster response at Day 30. Anti-PRP antibody titers ≥ 0.15 µg/ml and ≥ 1.0 µg/ml at Day 0 confirmed antibody persistence and booster response at Day 30.
Day 140 = Primary series; Day 0 = Pre-booster; and Day 30 = Post-booster titers.</description>
        <time_frame>Day 140 after primary vaccination, Day 0 (pre-vaccination), and Day 30 after final booster vaccination</time_frame>
        <population>Antibody responses were assessed in the Per Protocol Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: DTaP-IPV-Hep B-PRP~T + Prevenar™ Primary and Booster</title>
            <description>Participants who were previously primed with DTaP-IPV-Hep B-PRP~T received one dose of DTaP-IPV-Hep B-PRP~T vaccine and one dose of Prevenar (PCV7)</description>
          </group>
          <group group_id="O2">
            <title>Group 2:DTaP-IPV-HepB-PRP~T Primary/Infanrix Hexa+PCV7 Booster</title>
            <description>Participants who were previously primed with DTaP-IPV-Hep B-PRP~T received one dose of Infanrix Hexa vaccine and one dose of PCV7.</description>
          </group>
          <group group_id="O3">
            <title>Group 3:Infanrix Hexa Primary/DTaP-IPV-HepB-PRP~T+PCV7 Booster</title>
            <description>Participants who were previously primed with Infanrix Hexa vaccine received one dose of DTaP-IPV-Hep B-PRP~T and one dose of PCV7</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Hepatitis B and Haemophilus Influenzae Type B Post Primary Series Antibodies; Antibody Persistence, and Booster Response Following Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine or Infanrix Hexa Vaccine</title>
          <description>Anti-Hepatitis B antibodies were measured by the commercially available VITROS ECi/ECiQ Immunodiagnostic System. Anti-Haemophilus influenza type b capsular polyribosyl ribitol phosphate (PRP) antibodies were measured using a Farr type radioimmunoassay that used radiolabeled PRP (3H PRP) in the presence of 36Cl (volume marker). Anti-Hepatitis antibody titers ≥ 10 mIU/mL and ≥ 100 mIU/mL at Day 0 confirmed antibody persistence and booster response at Day 30. Anti-PRP antibody titers ≥ 0.15 µg/ml and ≥ 1.0 µg/ml at Day 0 confirmed antibody persistence and booster response at Day 30.
Day 140 = Primary series; Day 0 = Pre-booster; and Day 30 = Post-booster titers.</description>
          <population>Antibody responses were assessed in the Per Protocol Analysis Set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="396"/>
                <count group_id="O2" value="393"/>
                <count group_id="O3" value="260"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-Hep B Day 140 ≥10 mIU/mL (N = 393,392,260)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="391"/>
                    <measurement group_id="O2" value="391" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="260" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Hep B Day 140 ≥100 mIU/mL (N = 393,392,260)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="389"/>
                    <measurement group_id="O2" value="387" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="259" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Hep B Day 0 ≥10 mIU/mL (N = 396,391,259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="386"/>
                    <measurement group_id="O2" value="382" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="257" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Hep B Day 0 ≥100 mIU/mL (N = 396,391,259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="327"/>
                    <measurement group_id="O2" value="333" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="213" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Hep B Day 30 ≥10 mIU/mL (N = 395,393,259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="394"/>
                    <measurement group_id="O2" value="391" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="259" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Hep B Day 30 ≥100 mIU/mL (N = 395,393,259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="386"/>
                    <measurement group_id="O2" value="384" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="257" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRP Day 140 ≥0.15 µg/mL (N = 393,392,260)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="370"/>
                    <measurement group_id="O2" value="375" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="246" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRP Day 140 ≥1.0 µg/mL (N = 393,392,260)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="297"/>
                    <measurement group_id="O2" value="305" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="188" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRP Day 0 ≥0.15 µg/mL (N = 395,391,258)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="290"/>
                    <measurement group_id="O2" value="304" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="197" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRP Day 0 ≥1.0 µg/mL (N = 395,391,258)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="129" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="73" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRP Day 30 ≥0.15 µg/mL (N = 396,391,258)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="395"/>
                    <measurement group_id="O2" value="391" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="258" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRP Day 30 ≥1.0 µg/mL (N = 396,391,258)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="391"/>
                    <measurement group_id="O2" value="387" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="258" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Geometric Mean Titers to Vaccine Antibodies Post Primary Vaccination Series; Before and After Booster Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine or Infanrix Hexa Vaccine.</title>
        <description>Anti-Diphtheria antibodies were measured by a toxin neutralization test. Anti-Tetanus, anti-PT, and anti-FHA antibodies were measured by ELISA. Anti-Poliovirus types 1, 2, and 3 were measured by neutralization assay. Anti-Hepatitis B antibodies were measured by the commercially available VITROS ECi/ECiQ Immunodiagnostic System. Anti-PRP antibodies were measured using a Farr type radioimmunoassay that used radiolabeled PRP (3H PRP) in the presence of 36Cl (volume marker).
Day 140 = Primary series; Day 0 = Pre-booster; and Day 30 = Post-booster titers.</description>
        <time_frame>Day 140 after primary vaccination, Day 0 (pre-vaccination), and Day 30 after final booster vaccination</time_frame>
        <population>Geometric mean titers against vaccine antibodies were assessed in the Per Protocol Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: DTaP IPV Hep B PRP T + Prevenar™ Primary and Booster</title>
            <description>Participants who were previously primed with DTaP IPV Hep B PRP T received one dose of DTaP IPV Hep B PRP T vaccine and one dose of Prevenar (PCV7)</description>
          </group>
          <group group_id="O2">
            <title>Group 2DTaP IPV Hep B PRP T Primary/Infanrix Hexa+PCV7 Booster</title>
            <description>Participants who were previously primed with DTaP IPV Hep B PRP T received one dose of Infanrix Hexa vaccine and one dose of PCV7.</description>
          </group>
          <group group_id="O3">
            <title>Group 3Infanrix Hexa Primary/DTaP IPV Hep B PRP T+PCV7 Booster</title>
            <description>Participants who were previously primed with Infanrix Hexa vaccine received one dose of DTaP IPV Hep B PRP T and one dose of PCV7</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Geometric Mean Titers to Vaccine Antibodies Post Primary Vaccination Series; Before and After Booster Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine or Infanrix Hexa Vaccine.</title>
          <description>Anti-Diphtheria antibodies were measured by a toxin neutralization test. Anti-Tetanus, anti-PT, and anti-FHA antibodies were measured by ELISA. Anti-Poliovirus types 1, 2, and 3 were measured by neutralization assay. Anti-Hepatitis B antibodies were measured by the commercially available VITROS ECi/ECiQ Immunodiagnostic System. Anti-PRP antibodies were measured using a Farr type radioimmunoassay that used radiolabeled PRP (3H PRP) in the presence of 36Cl (volume marker).
Day 140 = Primary series; Day 0 = Pre-booster; and Day 30 = Post-booster titers.</description>
          <population>Geometric mean titers against vaccine antibodies were assessed in the Per Protocol Analysis Set.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="396"/>
                <count group_id="O2" value="393"/>
                <count group_id="O3" value="260"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-Diphtheria Day 140 (N=392,391,259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.265" lower_limit="0.237" upper_limit="0.295"/>
                    <measurement group_id="O2" value="0.254" lower_limit="0.227" upper_limit="0.285"/>
                    <measurement group_id="O3" value="0.251" lower_limit="0.220" upper_limit="0.286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Diphtheria Day 0 (N=390,390,257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.077" lower_limit="0.069" upper_limit="0.086"/>
                    <measurement group_id="O2" value="0.074" lower_limit="0.066" upper_limit="0.083"/>
                    <measurement group_id="O3" value="0.059" lower_limit="0.051" upper_limit="0.068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Diphtheria Day 30 (N=393,387,254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.55" lower_limit="5.07" upper_limit="6.08"/>
                    <measurement group_id="O2" value="4.40" lower_limit="3.99" upper_limit="4.86"/>
                    <measurement group_id="O3" value="6.05" lower_limit="5.41" upper_limit="6.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Tetanus Day 140 (N=392,391,258)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="1.39" upper_limit="1.61"/>
                    <measurement group_id="O2" value="1.54" lower_limit="1.44" upper_limit="1.65"/>
                    <measurement group_id="O3" value="1.80" lower_limit="1.68" upper_limit="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Tetanus Day 0 (N=389,387,255)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.208" lower_limit="0.188" upper_limit="0.231"/>
                    <measurement group_id="O2" value="0.224" lower_limit="0.200" upper_limit="0.251"/>
                    <measurement group_id="O3" value="0.201" lower_limit="0.180" upper_limit="0.225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Tetanus Day 30 (N=392,385,254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.72" lower_limit="5.21" upper_limit="6.27"/>
                    <measurement group_id="O2" value="5.21" lower_limit="4.78" upper_limit="5.68"/>
                    <measurement group_id="O3" value="7.52" lower_limit="6.63" upper_limit="8.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PT Day 140 (N=393,391,259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" lower_limit="94.0" upper_limit="106"/>
                    <measurement group_id="O2" value="102" lower_limit="96.6" upper_limit="108"/>
                    <measurement group_id="O3" value="97.0" lower_limit="90.1" upper_limit="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PT Day 0 (N=385,382,257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.43" lower_limit="6.63" upper_limit="8.32"/>
                    <measurement group_id="O2" value="8.47" lower_limit="7.52" upper_limit="9.56"/>
                    <measurement group_id="O3" value="7.41" lower_limit="6.38" upper_limit="8.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti PT D30 (N=391,383,254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154" lower_limit="143" upper_limit="166"/>
                    <measurement group_id="O2" value="191" lower_limit="178" upper_limit="206"/>
                    <measurement group_id="O3" value="140" lower_limit="127" upper_limit="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA Day 140 (N=391,390,259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179" lower_limit="169" upper_limit="190"/>
                    <measurement group_id="O2" value="187" lower_limit="176" upper_limit="199"/>
                    <measurement group_id="O3" value="120" lower_limit="112" upper_limit="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA Day 0 (N=389,384,255)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2" lower_limit="18.9" upper_limit="23.8"/>
                    <measurement group_id="O2" value="23.4" lower_limit="20.8" upper_limit="26.3"/>
                    <measurement group_id="O3" value="14.4" lower_limit="12.5" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA Day 30 (N=390,385,254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="316" lower_limit="293" upper_limit="342"/>
                    <measurement group_id="O2" value="418" lower_limit="386" upper_limit="454"/>
                    <measurement group_id="O3" value="260" lower_limit="231" upper_limit="293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 1 Day 140 (N=338,329,214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="656" lower_limit="587" upper_limit="734"/>
                    <measurement group_id="O2" value="705" lower_limit="625" upper_limit="796"/>
                    <measurement group_id="O3" value="1276" lower_limit="1098" upper_limit="1484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 1 Day 0 (N=338,326,213)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132" lower_limit="116" upper_limit="150"/>
                    <measurement group_id="O2" value="134" lower_limit="116" upper_limit="154"/>
                    <measurement group_id="O3" value="224" lower_limit="188" upper_limit="267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 1 Day 30 (N=339,327,212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2140" lower_limit="1937" upper_limit="2364"/>
                    <measurement group_id="O2" value="2633" lower_limit="2363" upper_limit="2933"/>
                    <measurement group_id="O3" value="2978" lower_limit="2592" upper_limit="3421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 2 Day 140 (N=338,327,214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1152" lower_limit="1035" upper_limit="1282"/>
                    <measurement group_id="O2" value="1241" lower_limit="1101" upper_limit="1398"/>
                    <measurement group_id="O3" value="1945" lower_limit="1676" upper_limit="2256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 2 Day 0 (N=337,328,213)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="251" lower_limit="214" upper_limit="294"/>
                    <measurement group_id="O2" value="289" lower_limit="245" upper_limit="341"/>
                    <measurement group_id="O3" value="380" lower_limit="313" upper_limit="461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 2 Day 30 (N=340,327,212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4232" lower_limit="3821" upper_limit="4688"/>
                    <measurement group_id="O2" value="4887" lower_limit="4372" upper_limit="5463"/>
                    <measurement group_id="O3" value="6369" lower_limit="5569" upper_limit="7283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 3 Day 140 (N=338,328,214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1169" lower_limit="1025" upper_limit="1332"/>
                    <measurement group_id="O2" value="1108" lower_limit="979" upper_limit="1255"/>
                    <measurement group_id="O3" value="1948" lower_limit="1647" upper_limit="2304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 3 Day 0 (N=338,326,213)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128" lower_limit="109" upper_limit="149"/>
                    <measurement group_id="O2" value="126" lower_limit="106" upper_limit="150"/>
                    <measurement group_id="O3" value="207" lower_limit="173" upper_limit="248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 3 Day 30 (N=340,326,212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3569" lower_limit="3164" upper_limit="4027"/>
                    <measurement group_id="O2" value="3322" lower_limit="2939" upper_limit="3755"/>
                    <measurement group_id="O3" value="6015" lower_limit="5244" upper_limit="6898"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Hepatitis B Day 140 (N=393,392,260)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3050" lower_limit="2715" upper_limit="3427"/>
                    <measurement group_id="O2" value="3180" lower_limit="2834" upper_limit="3568"/>
                    <measurement group_id="O3" value="2910" lower_limit="2556" upper_limit="3313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Hepatitis B Day 0 (N=396,391,259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="386" lower_limit="332" upper_limit="449"/>
                    <measurement group_id="O2" value="406" lower_limit="349" upper_limit="472"/>
                    <measurement group_id="O3" value="336" lower_limit="284" upper_limit="397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Hepatitis B Day 30 (N=395,393,259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8462" lower_limit="7154" upper_limit="10010"/>
                    <measurement group_id="O2" value="11218" lower_limit="9482" upper_limit="13272"/>
                    <measurement group_id="O3" value="9688" lower_limit="7940" upper_limit="11821"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRP Day 140 (N=393,392,260)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.19" lower_limit="2.69" upper_limit="3.78"/>
                    <measurement group_id="O2" value="3.60" lower_limit="3.05" upper_limit="4.25"/>
                    <measurement group_id="O3" value="2.13" lower_limit="1.78" upper_limit="2.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ant-PRP Day 0 (N=395,391,258)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.482" lower_limit="0.406" upper_limit="0.573"/>
                    <measurement group_id="O2" value="0.556" lower_limit="0.472" upper_limit="0.656"/>
                    <measurement group_id="O3" value="0.455" lower_limit="0.375" upper_limit="0.553"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRP Day 30 (N=396,391,258)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.4" lower_limit="37.0" upper_limit="48.6"/>
                    <measurement group_id="O2" value="41.5" lower_limit="36.6" upper_limit="47.0"/>
                    <measurement group_id="O3" value="56.5" lower_limit="48.4" upper_limit="65.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Immune Response Against Serotypes in the Prevenar Vaccine After Booster Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine or Infanrix Hexa Vaccine</title>
        <description>Anti-Streptococcus pneumococcal type specific antibody (anti-Pn PS) was measured by ELISA. Booster response to pneumococcal serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F was defined as antibody titers ≥0.35 µg/mL at Day 30.</description>
        <time_frame>Day 30 after final booster vaccination</time_frame>
        <population>Antibody responses against Prevenar vaccine serotypes were assessed in the Per-protocol Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: DTaP-IPV-Hep B-PRP~T + Prevenar™ Primary and Booster</title>
            <description>Participants who were previously primed with DTaP-IPV-Hep B-PRP~T received one dose of DTaP-IPV-Hep B-PRP~T vaccine and one dose of Prevenar (PCV7)</description>
          </group>
          <group group_id="O2">
            <title>Group 2:DTaP-IPV-HepB PRP~T Primary/Infanrix Hexa+PCV7 Booster</title>
            <description>Participants who were previously primed with DTaP-IPV-Hep B-PRP~T received one dose of Infanrix Hexa vaccine and one dose of PCV7.</description>
          </group>
          <group group_id="O3">
            <title>Group 3:Infanrix Hexa Primary/DTaP-IPV-HepB-PRP~T+PCV7 Booster</title>
            <description>Participants who were previously primed with Infanrix Hexa vaccine received one dose of DTaP-IPV-Hep B-PRP~T and one dose of PCV7</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Immune Response Against Serotypes in the Prevenar Vaccine After Booster Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine or Infanrix Hexa Vaccine</title>
          <description>Anti-Streptococcus pneumococcal type specific antibody (anti-Pn PS) was measured by ELISA. Booster response to pneumococcal serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F was defined as antibody titers ≥0.35 µg/mL at Day 30.</description>
          <population>Antibody responses against Prevenar vaccine serotypes were assessed in the Per-protocol Analysis Set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="396"/>
                <count group_id="O2" value="393"/>
                <count group_id="O3" value="260"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-Pneumococcal 4 (N=161,147,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                    <measurement group_id="O2" value="146" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="94" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Pneumococcal 6B (N=160,146,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155"/>
                    <measurement group_id="O2" value="145" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="93" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Pneumococcal 9V (N=161,147,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                    <measurement group_id="O2" value="147" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="94" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Pneumococcal 14 (N=161,147,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                    <measurement group_id="O2" value="147" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="94" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Pneumococcal 18C (N=161,147,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                    <measurement group_id="O2" value="147" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="94" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Pneumococcal 19F (N=161,147,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                    <measurement group_id="O2" value="144" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="94" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Pneumococcal 23F (N=158,145,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="144" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="93" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Geometric Mean Titers to Prevenar Vaccine Antibodies After Booster Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine or Infanrix Hexa Vaccine</title>
        <description>Anti-Streptococcus pneumococcal type specific antibody (anti-Pn PS) was measured by ELISA.</description>
        <time_frame>Day 30 after final booster vaccination</time_frame>
        <population>Geometric mean titers against Prevenar vaccine serotypes were assessed in the Per Protocol Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: DTaP-IPV-Hep B-PRP~T + Prevenar™ Primary and Booster</title>
            <description>Participants who were previously primed with DTaP-IPV-Hep B-PRP~T received one dose of DTaP-IPV-Hep B-PRP~T vaccine and one dose of Prevenar (PCV7)</description>
          </group>
          <group group_id="O2">
            <title>Group 2:DTaP-IPV-HepB-PRP~T Primary/Infanrix Hexa+PCV7 Booster</title>
            <description>Participants who were previously primed with DTaP-IPV-Hep B-PRP~T received one dose of Infanrix Hexa vaccine and one dose of PCV7.</description>
          </group>
          <group group_id="O3">
            <title>Group 3:Infanrix Hexa Primary/DTaP-IPV-HepB-PRP~T+PCV7 Booster</title>
            <description>Participants who were previously primed with Infanrix Hexa vaccine received one dose of DTaP-IPV-Hep B-PRP~T and one dose of PCV7</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Geometric Mean Titers to Prevenar Vaccine Antibodies After Booster Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine or Infanrix Hexa Vaccine</title>
          <description>Anti-Streptococcus pneumococcal type specific antibody (anti-Pn PS) was measured by ELISA.</description>
          <population>Geometric mean titers against Prevenar vaccine serotypes were assessed in the Per Protocol Analysis Set.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="396"/>
                <count group_id="O2" value="393"/>
                <count group_id="O3" value="260"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-Pneumococcal 4 (N=161,147,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.79" lower_limit="2.47" upper_limit="3.15"/>
                    <measurement group_id="O2" value="3.03" lower_limit="2.64" upper_limit="3.47"/>
                    <measurement group_id="O3" value="3.58" lower_limit="3.07" upper_limit="4.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Pneumococcal 6B (N=160,146,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.87" lower_limit="5.68" upper_limit="8.31"/>
                    <measurement group_id="O2" value="8.98" lower_limit="7.86" upper_limit="10.3"/>
                    <measurement group_id="O3" value="9.34" lower_limit="7.76" upper_limit="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Pneumococcal 9V (N=161,147,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.51" lower_limit="2.22" upper_limit="2.85"/>
                    <measurement group_id="O2" value="2.86" lower_limit="2.57" upper_limit="3.19"/>
                    <measurement group_id="O3" value="2.92" lower_limit="2.50" upper_limit="3.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Pneumococcal 14 (N=161,147,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" lower_limit="10.2" upper_limit="13.2"/>
                    <measurement group_id="O2" value="13.2" lower_limit="11.5" upper_limit="15.2"/>
                    <measurement group_id="O3" value="12.3" lower_limit="10.2" upper_limit="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Pneumococcal 18C (N=161,147,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.37" lower_limit="2.10" upper_limit="2.67"/>
                    <measurement group_id="O2" value="2.63" lower_limit="2.35" upper_limit="2.95"/>
                    <measurement group_id="O3" value="3.40" lower_limit="2.92" upper_limit="3.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Pneumococcal 19F (N=161,147,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.01" lower_limit="2.62" upper_limit="3.47"/>
                    <measurement group_id="O2" value="3.74" lower_limit="3.19" upper_limit="4.38"/>
                    <measurement group_id="O3" value="3.72" lower_limit="3.19" upper_limit="4.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Pneumococcal 23F (N=158,145,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.98" lower_limit="6.14" upper_limit="7.94"/>
                    <measurement group_id="O2" value="7.20" lower_limit="6.23" upper_limit="8.33"/>
                    <measurement group_id="O3" value="9.30" lower_limit="7.79" upper_limit="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Booster Response to Vaccine Antigens Before and After Booster Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine or Infanrix Hexa Vaccine By Age Strata</title>
        <description>Anti-PT and anti-FHA antibodies were measured by ELISA.</description>
        <time_frame>Day 0 (pre-vaccination) and Day 30 after final booster vaccination</time_frame>
        <population>Booster responses to vaccine antigens were assessed in the Per Protocol Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: DTaP-IPV-Hep B-PRP~T + Prevenar™ Primary and Booster</title>
            <description>Participants who were previously primed with DTaP-IPV-Hep B-PRP~T received one dose of DTaP-IPV-Hep B-PRP~T vaccine and one dose of Prevenar (PCV7)</description>
          </group>
          <group group_id="O2">
            <title>Group 2:DTaP-IPV-HepB-PRP~T Primary/Infanrix Hexa+PCV7 Booster</title>
            <description>Participants who were previously primed with DTaP-IPV-Hep B-PRP~T received one dose of Infanrix Hexa vaccine and one dose of PCV7.</description>
          </group>
          <group group_id="O3">
            <title>Group 3:Infanrix Hexa Primary/DTaP-IPV-HepB-PRP~T+PCV7 Booster</title>
            <description>Participants who were previously primed with Infanrix Hexa vaccine received one dose of DTaP-IPV-Hep B-PRP~T and one dose of PCV7</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Booster Response to Vaccine Antigens Before and After Booster Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine or Infanrix Hexa Vaccine By Age Strata</title>
          <description>Anti-PT and anti-FHA antibodies were measured by ELISA.</description>
          <population>Booster responses to vaccine antigens were assessed in the Per Protocol Analysis Set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="396"/>
                <count group_id="O2" value="393"/>
                <count group_id="O3" value="260"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PT ≥12 to &lt;15 month Day 0 (N=104,105,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="104" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="61" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PT ≥12 to &lt;15 moth Day 30 4-fold N=103,102,60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="92" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="53" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PT ≥12 to &lt;15 months Booster (N=103,102,60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="99" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="56" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PT ≥15 to &lt;19 month Day 0 (N=142,128,96)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="118" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="86" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PT ≥15 to &lt;19 moth Day 30 4-fold N=140,126,95</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132"/>
                    <measurement group_id="O2" value="121" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="89" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PT ≥15 to &lt;19 month Booster (N=140,126,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138"/>
                    <measurement group_id="O2" value="125" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="94" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PT ≥19 to ≤24 months Day 0 (N=139,149,100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="127" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="78" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AntiPT ≥19 to ≤24 month Day 30 4 fold N=137,146,97</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                    <measurement group_id="O2" value="138" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="92" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PT ≥19 to ≤24 months Booster (N=137,146,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="141" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="95" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA ≥12 to &lt;15 months Day 0 (N=103,105,59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="105" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="59" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA ≥12 to &lt;15 mos Day 30 4-fold N=103,101,58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="78" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="53" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA ≥12 to &lt;15 months Booster (N=103,101,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="99" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="58" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA ≥15 to &lt;19 month Day 0 (N=143,130,96)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="130" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="95" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA ≥15 to &lt;19 mos Day 30 4-fold N=140,128,96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="118" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="88" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA ≥15 to &lt;19 months Booster (N=140,128,96)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="124" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="94" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA ≥19 to ≤24 month Day 0 (N=143,149,100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="149" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="99" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA ≥19 to ≤24 mos Day 30 4-fold N=141,147,98</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="138" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="94" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA ≥19 to ≤ 24 months Booster (N=141,147,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138"/>
                    <measurement group_id="O2" value="144" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="97" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Geometric Mean Titers to Vaccine Antigens After Booster Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine or Infanrix Hexa Vaccine by Age Strata</title>
        <description>Anti-Diphtheria antibodies were measured by a toxin neutralization test. Anti-FHA antibodies were measured by ELISA. Anti-Poliovirus types 1, 2, and 3 were measured by neutralization assay.</description>
        <time_frame>Day 30 after final booster vaccination</time_frame>
        <population>Geometric mean titers to vaccine antigens were assessed in the Per Protocol Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: DTaP-IPV-Hep B-PRP~T + Prevenar™ Primary and Booster</title>
            <description>Participants who were previously primed with DTaP-IPV-Hep B-PRP~T received one dose of DTaP-IPV-Hep B-PRP~T vaccine and one dose of Prevenar (PCV7)</description>
          </group>
          <group group_id="O2">
            <title>Group 2:DTaP-IPV-HepB-PRP~T Primary/Infanrix Hexa+PCV7 Booster</title>
            <description>Participants who were previously primed with DTaP-IPV-Hep B-PRP~T received one dose of Infanrix Hexa vaccine and one dose of PCV7.</description>
          </group>
          <group group_id="O3">
            <title>Group 3:Infanrix Hexa Primary/DTaP-IPV-HepB-PRP~T+PCV7 Booster</title>
            <description>Participants who were previously primed with Infanrix Hexa vaccine received one dose of DTaP-IPV-Hep B-PRP~T and one dose of PCV7</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Geometric Mean Titers to Vaccine Antigens After Booster Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine or Infanrix Hexa Vaccine by Age Strata</title>
          <description>Anti-Diphtheria antibodies were measured by a toxin neutralization test. Anti-FHA antibodies were measured by ELISA. Anti-Poliovirus types 1, 2, and 3 were measured by neutralization assay.</description>
          <population>Geometric mean titers to vaccine antigens were assessed in the Per Protocol Analysis Set.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="396"/>
                <count group_id="O2" value="393"/>
                <count group_id="O3" value="260"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-Diphtheria ≥12 to &lt;15 months (N=103,107,59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.20" lower_limit="2.72" upper_limit="3.76"/>
                    <measurement group_id="O2" value="2.73" lower_limit="2.30" upper_limit="3.24"/>
                    <measurement group_id="O3" value="3.82" lower_limit="3.01" upper_limit="4.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Diphtheria ≥15 to &lt;19 months (N=144,129,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.39" lower_limit="5.56" upper_limit="7.34"/>
                    <measurement group_id="O2" value="4.77" lower_limit="3.98" upper_limit="5.72"/>
                    <measurement group_id="O3" value="6.56" lower_limit="5.43" upper_limit="7.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Diphtheria ≥19 to ≤24 months (N=146,151,100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.14" lower_limit="6.17" upper_limit="8.26"/>
                    <measurement group_id="O2" value="5.77" lower_limit="5.00" upper_limit="6.66"/>
                    <measurement group_id="O3" value="7.34" lower_limit="6.30" upper_limit="8.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA ≥12 to &lt;15 months (N=103,105,60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="235" lower_limit="209" upper_limit="263"/>
                    <measurement group_id="O2" value="268" lower_limit="233" upper_limit="308"/>
                    <measurement group_id="O3" value="197" lower_limit="156" upper_limit="248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA ≥15 to &lt;19 months (N=143,130,96)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="339" lower_limit="294" upper_limit="392"/>
                    <measurement group_id="O2" value="453" lower_limit="392" upper_limit="524"/>
                    <measurement group_id="O3" value="280" lower_limit="236" upper_limit="331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA ≥19 to ≤24 months (N=144,150,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="365" lower_limit="322" upper_limit="414"/>
                    <measurement group_id="O2" value="533" lower_limit="473" upper_limit="599"/>
                    <measurement group_id="O3" value="287" lower_limit="232" upper_limit="356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 3 ≥12 to &lt;15 months (N=87,92,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2509" lower_limit="1944" upper_limit="3240"/>
                    <measurement group_id="O2" value="2616" lower_limit="2098" upper_limit="3263"/>
                    <measurement group_id="O3" value="5617" lower_limit="4006" upper_limit="7876"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 3 ≥15 to &lt;19 months (N=128,114,81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3944" lower_limit="3265" upper_limit="4764"/>
                    <measurement group_id="O2" value="3261" lower_limit="2585" upper_limit="4113"/>
                    <measurement group_id="O3" value="5409" lower_limit="4359" upper_limit="6713"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 3 ≥19 to ≤24 months (N=125,120,86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4119" lower_limit="3398" upper_limit="4993"/>
                    <measurement group_id="O2" value="4061" lower_limit="3387" upper_limit="4869"/>
                    <measurement group_id="O3" value="6889" lower_limit="5583" upper_limit="8499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting a Solicited Injection Site or Systemic Reactions Following Booster Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine or Infanrix Hexa Vaccine</title>
        <description>Solicited injection site: Pain, Erythema, Swelling, and Extensive swelling of vaccinated limb; Solicited systemic reactions: Pyrexia (Temperature), Vomiting, Crying, Somnolence, Anorexia, and Irritability. Grade 3 Injection site: Pain, Cries if limb is moved or reduced movement; Erythema and Swelling, ≥5 cm; Extensive swelling of limb, Severe. Grade 3 Systemic reactions: Pyrexia (Temperature) &gt;39.5˚C; Vomiting, ≥ 6 times per 24 hours or needing parenteral nutrition; Crying, &gt;3 hours; Somnolence, Sleeping often or difficulty waking; Anorexia, refuses ≥3 meals; and Irritability, Inconsolable.</description>
        <time_frame>Day 0 up to Day 7 after final booster vaccination</time_frame>
        <population>Solicited injection site reactions and systemic reactions were assessed in the Safety Analysis Set, which includes all persons who received the study or control vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: DTaP-IPV-Hep B-PRP~T + Prevenar™ Primary and Booster</title>
            <description>Participants who were previously primed with DTaP-IPV-Hep B-PRP~T received one dose of DTaP-IPV-Hep B-PRP~T vaccine and one dose of Prevenar (PCV7)</description>
          </group>
          <group group_id="O2">
            <title>Group 2:DTaP-IPV-HepB-PRP~T Primary/Infanrix Hexa+PCV7 Booster</title>
            <description>Participants who were previously primed with DTaP-IPV-Hep B-PRP~T received one dose of Infanrix Hexa vaccine and one dose of PCV7.</description>
          </group>
          <group group_id="O3">
            <title>Group 3:Infanrix Hexa Primary/DTaP-IPV-HepB-PRP~T+PCV7 Booster</title>
            <description>Participants who were previously primed with Infanrix Hexa vaccine received one dose of DTaP-IPV-Hep B-PRP~T and one dose of PCV7</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting a Solicited Injection Site or Systemic Reactions Following Booster Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine or Infanrix Hexa Vaccine</title>
          <description>Solicited injection site: Pain, Erythema, Swelling, and Extensive swelling of vaccinated limb; Solicited systemic reactions: Pyrexia (Temperature), Vomiting, Crying, Somnolence, Anorexia, and Irritability. Grade 3 Injection site: Pain, Cries if limb is moved or reduced movement; Erythema and Swelling, ≥5 cm; Extensive swelling of limb, Severe. Grade 3 Systemic reactions: Pyrexia (Temperature) &gt;39.5˚C; Vomiting, ≥ 6 times per 24 hours or needing parenteral nutrition; Crying, &gt;3 hours; Somnolence, Sleeping often or difficulty waking; Anorexia, refuses ≥3 meals; and Irritability, Inconsolable.</description>
          <population>Solicited injection site reactions and systemic reactions were assessed in the Safety Analysis Set, which includes all persons who received the study or control vaccine.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="416"/>
                <count group_id="O2" value="415"/>
                <count group_id="O3" value="275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site Pain (N=413,412,272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="232"/>
                    <measurement group_id="O2" value="205" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="160" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 inj. site Pain (N=413,412,272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Erythema (N=413,412,272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="100" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="86" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 inj. site Erythema (N=413,412,272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Swelling (N=412,412,272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="56" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="49" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 inj. site Swelling (N=412,412,272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extensive swelling of limb (N=413,412,272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Extensive swelling of limb (N=413,412,272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pyrexia (N=413,412,272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="99" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="91" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pyrexia (N=413,412,272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (N=413,412,272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="39" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="19" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Vomiting (N=413,412,272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crying (N=413,412,272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148"/>
                    <measurement group_id="O2" value="139" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="102" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Crying (N=413,412,272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somnolence (N=413,412,272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="113" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="85" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Somnolence (N=413,412,272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anorexia (N=413,412,272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118"/>
                    <measurement group_id="O2" value="121" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="90" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Anorexia (N=413,412,272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (N=413,412,272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201"/>
                    <measurement group_id="O2" value="176" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="146" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability (N=413,412,272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting a Solicited Injection Site Following Booster Vaccination With Prevenar Vaccine</title>
        <description>Solicited injection site: Pain, Erythema, Swelling, and Extensive swelling of vaccinated limb. Grade 3 Injection site: Pain, cries if limb is moved or reduced movement; Erythema and Swelling, ≥5 cm; and Extensive swelling of limb, Severe.</description>
        <time_frame>Day 0 up to Day 7 after final booster vaccination</time_frame>
        <population>Solicited injection site reactions were assessed in the Safety Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: DTaP-IPV-Hep B-PRP~ T + Prevenar™ Primary and Booster</title>
            <description>Participants who were previously primed with DTaP-IPV-Hep B-PRP~T received one dose of DTaP-IPV-Hep B-PRP~T vaccine and one dose of Prevenar (PCV7)</description>
          </group>
          <group group_id="O2">
            <title>Group 2: DTaP-IPV-HepB-PRP~Tprimary/Infanrix Hexa+PCV7 Booster</title>
            <description>Participants who were previously primed with DTaP-IPV-Hep B-PRP~T received one dose of Infanrix Hexa vaccine and one dose of PCV7.</description>
          </group>
          <group group_id="O3">
            <title>Group 3:Infanrix Hexa Primary/DTaP-IPV-HepB-PRP~T+PCV7 Booster</title>
            <description>Participants who were previously primed with Infanrix Hexa vaccine received one dose of DTaP-IPV-Hep B-PRP~T and one dose of PCV7</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting a Solicited Injection Site Following Booster Vaccination With Prevenar Vaccine</title>
          <description>Solicited injection site: Pain, Erythema, Swelling, and Extensive swelling of vaccinated limb. Grade 3 Injection site: Pain, cries if limb is moved or reduced movement; Erythema and Swelling, ≥5 cm; and Extensive swelling of limb, Severe.</description>
          <population>Solicited injection site reactions were assessed in the Safety Analysis Set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="416"/>
                <count group_id="O2" value="415"/>
                <count group_id="O3" value="275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site Pain (N=413,412,272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="224"/>
                    <measurement group_id="O2" value="184" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="140" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection site Pain (N=413,412,272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Erythema (N=413,412,272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="77" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="52" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection site Erythema (N=413,412,272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Swelling (N=413,412,272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="42" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="33" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection site Swelling (N=413,412,272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from Day 0 (post-vaccination) up to Day 30 after final booster vaccination.</time_frame>
      <desc>The total number (N) for solicited adverse events in the table reflects those participants for which the diary cards were returned and for which data were available for the event during the period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1: DTaP-IPV-Hep B-PRP~T + Prevenar™ Primary and Booster</title>
          <description>Participants who were previously primed with DTaP-IPV-Hep B-PRP~T received one dose of DTaP-IPV-Hep B-PRP~T vaccine and one dose of Prevenar (PCV7)</description>
        </group>
        <group group_id="E2">
          <title>Group 2:DTaP-IPV-HepB-PRP~T Primary/Infanrix Hexa+PCV7 Booster</title>
          <description>Participants who were previously primed with DTaP-IPV-Hep B-PRP~T received one dose of Infanrix Hexa vaccine and one dose of PCV7.</description>
        </group>
        <group group_id="E3">
          <title>Group 3:Infanrix Hexa Primary/DTaP-IPV-HepB-PRP~T+PCV7 Booster</title>
          <description>Participants who were previously primed with Infanrix Hexa vaccine received one dose of DTaP-IPV-Hep B-PRP~T and one dose of PCV7</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 12.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="415"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="275"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Idiopathic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="275"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="275"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>Kawasaki's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>Osteomyelitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="416"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="415"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="275"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="275"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="416"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="275"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="275"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="416"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="275"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.00</frequency_threshold>
        <default_vocab>MedDRA version 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="253" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="221" subjects_at_risk="415"/>
                <counts group_id="E3" subjects_affected="168" subjects_at_risk="275"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="34" subjects_affected="34" subjects_at_risk="413"/>
                <counts group_id="E2" events="39" subjects_affected="39" subjects_at_risk="412"/>
                <counts group_id="E3" events="19" subjects_affected="19" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site Pain</sub_title>
                <counts group_id="E1" events="232" subjects_affected="232" subjects_at_risk="416"/>
                <counts group_id="E2" events="205" subjects_affected="205" subjects_at_risk="412"/>
                <counts group_id="E3" events="160" subjects_affected="160" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Injection site Erythema</sub_title>
                <counts group_id="E1" events="112" subjects_affected="112" subjects_at_risk="413"/>
                <counts group_id="E2" events="100" subjects_affected="100" subjects_at_risk="412"/>
                <counts group_id="E3" events="86" subjects_affected="86" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Injection site Swelling</sub_title>
                <counts group_id="E1" events="60" subjects_affected="60" subjects_at_risk="412"/>
                <counts group_id="E2" events="56" subjects_affected="56" subjects_at_risk="412"/>
                <counts group_id="E3" events="49" subjects_affected="49" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="114" subjects_affected="114" subjects_at_risk="413"/>
                <counts group_id="E2" events="99" subjects_affected="99" subjects_at_risk="412"/>
                <counts group_id="E3" events="91" subjects_affected="91" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="416"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="415"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="275"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="118" subjects_affected="118" subjects_at_risk="413"/>
                <counts group_id="E2" events="121" subjects_affected="121" subjects_at_risk="412"/>
                <counts group_id="E3" events="90" subjects_affected="90" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="124" subjects_affected="124" subjects_at_risk="413"/>
                <counts group_id="E2" events="113" subjects_affected="113" subjects_at_risk="412"/>
                <counts group_id="E3" events="85" subjects_affected="85" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" events="148" subjects_affected="148" subjects_at_risk="413"/>
                <counts group_id="E2" events="139" subjects_affected="139" subjects_at_risk="412"/>
                <counts group_id="E3" events="102" subjects_affected="102" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="201" subjects_affected="201" subjects_at_risk="413"/>
                <counts group_id="E2" events="176" subjects_affected="176" subjects_at_risk="412"/>
                <counts group_id="E3" events="146" subjects_affected="146" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

